June 18, 4:23 PMVaccines ExaminerNorma Erickson
VAERS (vaccine adverse events reporting system) Reports: 73 fatalities, 3771 did not recover events, 610 disabled, 355 life threatening events, 7858 emergency room visits, and 1865 hospitalizations associated with HPV vaccinations as of May 2010. Perhaps there would not be so many of these serious adverse events if public health officials, governments and vaccine manufacturers paid more attention to the Human papillomavirus vaccines WHO position paper.
Published April 10, 2009, this paper was primarily intended to provide guidance to managers of immunization programs around the world and national public health officials. It also contains helpful information for international funding agencies, vaccine manufacturers, and the medical community.
When you examine the statements contained in this position paper (in bold) and the questions raised, you have to wonder if anyone involved with vaccination programs being conducted around the world has actually read the document.
Statements from WHO’s official HPV vaccines position paper include:
- Phase II and III clinical trials were conducted in females aged 15 to 26: Why do many countries recommend HPV vaccines to children as young as 9, the United States included? Are these programs nothing more than phase IV clinical trials?
- Collecting cervical specimens from girls or young adolescents is usually considered unethical or impractical: HPV vaccines do not provide any benefit if the recipient is already positive for the strains in the vaccines. Quite the opposite in fact, if someone is positive for HPV 16/18 prior to vaccination the chance of precancerous lesions can increase by up to 44.6% for Gardasil, and 32.5% for Cervarix. Why are vaccine programs targeting girls too young to be pre-screened for ethical or practical reasons?
- Clinical efficacy trials for both vaccines demonstrate that protection lasts for at least five years: Why are people under the impression protection lasts a lifetime?